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748Objectives: Transfemoral application of pulmonary heart valves has been studied for the past 10 years. Neverthe-
less, size restriction of percutaneous heart valved stents is still imminent.
Methods: In this study we implanted percutaneously a novel, low-profile polyurethane valved stent. Percutane-
ous implantation in pulmonary position was evaluated in 7 sheep. The new valved stent fits into a 14F delivery
device. The self-expanding nitinol stent was produced by using a dip-coating technique, and a modified commer-
cially available endovascular stent graft system served as a delivery device. The valved stents were deployed di-
rectly over the native pulmonary valve under fluoroscopic control. Transthoracic echocardiography was
performed after 4 weeks. At the time of explantation, the animals were reanalyzed and killed. Angiography
was performed at implantation and at the end of the study. Explanted constructs were analyzed macroscopically
and microscopically.
Results: Angiography and echocardiography in all animals demonstrated orthotopic position of the stents at the
time of implantation and after 4 weeks. During the deployment procedure, rhythm disturbances occurred in all
animals. The peak-to-peak transvalvular gradient was 2.3 1.2 mm Hg initially and 4.1 2.4 mm Hg at follow-
up. One-month follow-up confirmed competent neovalves without any paravalvular leakage. Gross morphology
demonstrated good opening and closure characteristics. No calcification was seen macroscopically, and surround-
ing tissue was free of calcification.
Conclusion: In the present study we demonstrated successful merging of 2 novel technologies for percutaneous
treatment of pulmonary valve diseases using polyurethane stent valve constructs. (J Thorac Cardiovasc Surg
2010;139:748-52)Percutaneous pulmonary and aortic valve implantations
were clinically introduced by Bonhoeffer and colleagues1
in 2000 and Cribier and associates2 in 2002. This appealing
new approach to treating valve disease has made remarkable
progress. Recently, Bonhoeffer and colleagues1 emphasized
the potential effect of percutaneous valved stent implanta-
tion on right ventricular outflow tract (RVOT) reinterven-
tion. This method proved to be a promising additional and
complementary approach to a successful surgical program.3
Nevertheless, the resulting anatomic spectrum from pulmo-
nary regurgitation after surgical intervention for congenital
RVOT disease is broad. With currently available stents, it
is not possible to treat all concerned patients. So far, wide
or severely calcified and kinked RVOTs are not suitable
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The Journal of Thoracic and Cardiovascular Surgand interventional hybrid approaches are under investigation
to overcome these problems.4,5 Our group demonstrated the
feasibility of totally percutaneous transfemoral pulmonary
valve implantation in an ovine model using self-expanding
nitinol stents.6 Nevertheless, the overall size of the valved
stent should be reduced. With younger patients, especially
children, smaller outer diameters of the delivery system
(<18F) should be used. To circumvent size restrictions of
percutaneous heart valves, we designed a novel low-profile
valved stent made of polyurethane that fits into a 14F de-
vice.7
The aim of this study was to evaluate the functioning of
percutaneously implanted self-expanding stents carrying
a polyurethane valve in the pulmonary position. This study
was performed in juvenile sheep during a 1-month period
using angiographic, echocardiographic, hemodynamic, and
macroscopic analyses and histologic assessment.MATERIALS AND METHODS
Animal Model and Implantation Procedure
Nine studies in sheep weighing 32 to 40 kg are reported. Animals re-
ceived humane care in accordance with the ‘‘Principles of laboratory animal
care’’ and the ‘‘Guide for the care and use of laboratory animals’’ (National
Institutes of Health, publication no. 85-23, revised 1985). An ethical com-
mittee on animal research at Kiel University approved the protocol.
Anesthesia and implantation were carried out as previously described.6
Seven-French sheaths were introduced into the left femoral artery and
vein of 7 sheep for hemodynamic measurement. The novel low-profileery c March 2010
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(Figure 1). This was percutaneously inserted into the right groin, and the
valved stents were deployed directly over the native pulmonary valve under
fluoroscopic control.6 The delivery system was removed, as previously de-
scribed,6 and animals were analyzed for various parameters, as described
below. Afterward, the sheep were returned to the animal facility, where their
general health was checked daily. They were not treated for anticoagulation
or inhibition of platelet aggregation. One month later, the animals were re-
analyzed (see below) and killed.
Stent Design
Radially self-expanding nitinol stents (Nitinol Devices & Components,
Inc, Fremont, Calif) were used in the present study. The stent wires are
soft and highly malleable, molding 2 ranks of 14 rhombs each. Bare stents
were 28 mm in length and 22 or 24 mm in diameter when fully expanded.
We used a dip-coating technique. Polyurethane was dissolved with an or-
ganic dissolver, and after evaporation of the solvent, the valve was cured.
Angiography
An angiographic unit (Optimus M 200; Philips Medizin Systeme, Ham-
burg, Germany) was used for fluoroscopic assessment of the position and
function of the polyurethane valves.
Echocardiographic and Hemodynamic
Measurements
Transthoracic echocardiography (TTE) was performed at 4 weeks’ fol-
low-up, as previously described.6 Arterial pressure, right ventricular pres-
sure, and pulmonary artery pressure were measured, as previously
described.6
Macroscopic Examination
Valved stents were grossly inspected, and photographs were taken. Spe-
cial attention was given to confirm retraction of the cusps or detect any de-
formed or indurated parts of the valve. The atrial and ventricular chambers
and the pulmonary artery were exposed to look for catheter-induced damage
or penetration of stent struts.
Histologic Analysis
The surrounding tissue of the pulmonary artery was fixed in 4% formalin
for 72 hours, soaked in tap water for 2 hours, dehydrated in graded alcohol,
and finally embedded in paraffin (Merck, Darmstadt, Germany). Sections
(1–2 mm) of each tissue sample were deparaffinized and rehydrated. For
general morphology, serial sections were stained with hematoxylin and
eosin stain (cellular components and nuclei). For identification of calcifica-
tion, von Kossa staining was conducted. The slides were thoroughly rinsed,
with repeated turning of the slide during staining to avoid edge-effect
artifacts. Sections were analyzed and documented by using common
bright-field light microscopy (Axiovert S 100; Zeiss, Jena, Germany).
Statistics
Values are presented as means  standard deviations. Data were ana-
lyzed with the paired Student t test to compare related normally distributed
data, and nonnormally distributed data by using SPSS 10.1 software (SPSS,
Inc, Chicago, Ill). P values of less than .05 were considered statistically
significant.The Journal of Thoracic and CaRESULTS
Eight of 9 sheep from the study survived the entire 4-week
observation period.One sheep died due to ventricular arrhyth-
mia during the implantation procedure, and 1 sheep had endo-
carditis. Data were analyzed from all other sheep (n¼ 7). The
mean diameter of the pulmonary annuli was 17.7  0.6 mm
(range, 17.0–18.0 mm), as revealed by angiography.
Implanted valved stents with a maximal outer diameter of
22.1 to 24.2 mm were used. The mean duration of the pro-
cedure from insertion of the application device through the
sheath to deployment was 56 seconds.Echocardiography
TTE demonstrated a laminar blood flow across the valved
stents in the analyzed cases. One mild central insufficiency
and no paravalvular leakage were detected. Left ventricular
and right ventricular function and dimensions appeared nor-
mal. The mean systolic internal diameter of the valved niti-
nol stents was measured at 16.5  1.5 mm, and the mean
internal diastolic diameter was measured at 19.6  0.7 mm.Angiography
Angiography showed orthotopic positioning of the stents
at the time of implantation in all animals. In contrast, all an-
imals demonstrated orthotopic position, with the exception
of 1 animal, in which the stent was shown to be in the pul-
monary artery at approximately 1 cm distal of the base of
the pulmonary valve after 4 weeks. One-month angiography
demonstrated good opening and closure characteristics.
Angiography revealed competent valved stents in all 7 sur-
viving sheep after 4 weeks (Figure 2). Paravalvular leakages
were not observed.Hemodynamic Measurements
During the deployment procedure, rhythm disturbances
occurred in all animals. The peak-to-peak gradient across
the valved stent was 2.3  1.2 mm Hg initially and 4.1 
2.4 mm Hg at follow-up. Hemodynamic data are shown in
Table 1.Macroscopic Examination
Postmortem examination after 1 month confirmed the cor-
rect position of the valved stent in 6 of 7 sheep (Figure 3, A).
In 1 sheep the valved stent was found in the pulmonary
artery at approximately 1 cm distal to the base of the
pulmonary valve.
No paravalvular defects were visible. The valved stents
were pliable, and the leaflets were thin without indurations.
Slight fibrous overgrowth was seen at the outflow portions of
the valved stents in 3 of 7 cases (Figure 3, B). Cardiac struc-
tures were unscathed. Nomacroscopic damage was noted. In
particular, there was no penetration of any of the stentrdiovascular Surgery c Volume 139, Number 3 749
FIGURE 1. A, Top view of a self-expanding nitinol stent (length, 28 mm; diameter, 22 mm; Nitinol Devices & Components, Inc) containing a 3-leaflet
polyurethane valve. B, Lateral view of the top of the delivery system including a polyurethane valved stent.
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macroscopically.Histology
The surrounding tissue of the pulmonary artery showed
normal hematoxylin and eosin staining (Figure 4, A) and
no calcification after von Kossa staining (Figure 4, B).DISCUSSION
Surgical reconstruction of the RVOT in children with
congenital heart defects, including pulmonary valve replace-
ment, is connected with low morbidity and mortality,8 and
implantation of a pulmonary homograft is considered the
gold standard. However, graft deterioration is very common,
and therefore reoperations are often unavoidable in adoles-FIGURE 2. Correct position of the polyurethane valved stent in the pulmo-
nary position in an ovine model. After 4 weeks, no regurgitation was as-
sessed.
750 The Journal of Thoracic and Cardiovascular Surgcents.9 In contrast, percutaneous pulmonary valve implanta-
tion is emerging as an alternative or additional option for
a successful surgical scheme, recently being introduced
into clinical practice.1 Bonhoeffer and colleagues10 success-
fully performed 155 procedures with no early deaths and
only 4 procedural complications. The survival rate of these
155 patients after 83 month was 96.9%. The advantages
of minimally invasive procedures are obvious (ie, smaller in-
cisions, less postoperative pain, shorter hospital stay, and
lower costs). Therefore balloon-expandable valved stents
are already used in clinical practice.3 The advantage of xeno-
grafts is no need of anticoagulation and a high biocompati-
bility. For homografts, there is a relative resistance against
infections and a high biocompatibility. The disadvantage
of both is that they have no growth potential and a limitation
of durability and degeneration. Transcatheter valves were
implanted under fluoroscopic control, and this implantation
procedure is better for the patient.
The potential advantages of nitinol stents regarding pres-
ervation of the valve and deployment have been previously
discussed.6
In this studyweused the percutaneouspolyurethanevalved
stent implant, which fits into a 14F delivery device.7 Polyure-
thane has demonstrated the best biocompatibility, durability,
and resistance to thromboembolism among all polymers, and
therefore it was also used for a variety of medical devices.
However, until now, even thoughmanufacturedpolyurethane
has had sufficientmechanical strength and flexibility for heartTABLE 1. Hemodynamic data
Valved stent implantation
Before After 1-mo follow-up P value
RVP, systolic 15  0 15.5  0 20.3  6.5 <.0006
RVP, diastolic 4  0 4  0.5 2.4  1.9 NS
RVP, mean 9  0 8.5  0.25 8.8  3.3 NS
PAP, systolic 12.3  0.8 12.5  0.9 18  3.4 <.001
PAP, diastolic 9  0.6 9.5  0.8 6.2  3.8 NS
PAP, mean 10.1  0.4 10.5  0.6 12  2.9 NS
RVP, Right ventricular pressure; PAP, pulmonary artery pressure.
ery c March 2010
FIGURE 3. Gross morphology of polyurethane pulmonary valved stent. A, The native pulmonary valve can be seen (arrow). B, At the distal part of the stent,
mild fibrosis was observed at the explanted stent.
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vitro, it has performed disappointingly when implanted in
vivo. Polyurethane is one of the most important categories
of synthetic polymers used for both short- and long-term
blood-contact medical applications. The development of
polymeric heart valve substitutes goes back to the end of
the 1950s, when Roe and Moore11 implanted an aortic pros-
thesis made of silicone rubber in human subjects. Many poly-
meric heart valves were tested in vitro and in vivo, including
valves made of silicone, polytetrafluoroethylene (Teflon;
Mecora, Aachen, Germany), polyethylene terephthalate (Da-
cron;Mecora), polyvinylchloride, and polyurethane. None of
these valves proved to be adequate for human implantation
because material degradation and thrombogenicity remained
unsolved problems. In the 1980s and 1990s, new insight was
obtained to show that durability not only depends on the valve
polymer but also is mainly influenced by the manufacturing
process and design. The aim was to manufacture a so-called
biomechanical valve, a prosthesis that is made only of artifi-
cialmaterial. Nevertheless, the valve is flexible because of the
material properties of polyurethane. Now the hope is to com-
bine 2 advantages: long-term durability and no necessity for
permanent anticoagulation.
In the present study angiographic examination mainly
demonstrated correct positioning and a good adjustment ofFIGURE 4. Histologic analyses. A, Normal structure and cells of the surround
staining. B, Von Kossa staining of the surrounding tissue was conducted for ca
The Journal of Thoracic and Cathe pulmonary diameter, annular size, and valved stent diam-
eter. The soft nitinol stent’s ability to adapt to the surrounding
structure was conducive to physiologic blood flow in the
great arteries: the new valved stent did not negatively affect
right or left ventricular function, which was shown by hemo-
dynamic measurements. The echocardiogram demonstrated
the same contractility and relaxation properties of the left
and right ventricles before and after implantation of the poly-
urethane valve. A low transvalvular gradient was seen before
implantation and after 1 month follow-up. Macroscopic and
histologic assessment revealed no calcifications.
In this study we confirmed the implantability of our new
polyurethane valved stent. During the 4-week observation
period, no defects of the leaflets were detected. Angiography
demonstrated orthotopic position and showed good opening
and closing capacity. Neither immune reactions nor throm-
bosis was observed. In contrast, mild fibrosis was seen in
the distal part of the valved stent. Therefore it was not nec-
essary to use any anticoagulation or immune-suppressive
medication.
Wheatley and coworkers12 used polyurethane, bileaflet
mechanical (ATS Medical, Inc, Minneapolis, Minn), and
Carpentier–Edwards porcine (Edwards Lifesciences, Irvine,
Calif) valves for their study. These valves were implanted in
the mitral position of growing sheep and explanted after 6ing tissue were seen with the overview by means of hematoxylin and eosin
lcification. No calcifications were detected.
rdiovascular Surgery c Volume 139, Number 3 751
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showed that the thrombogenicity of the polyurethane valves
was lower compared with that of the mechanical valves. In
addition, this research group indicated that the polyurethane
valve in the mitral position was superior to a bioprosthesis.
Daebritz and associates13 analyzed the implantation of
a flexible, polymeric aortic valve, which underwent long-
term in vitro and in vivo testing in a growing calve animal
model. These polyurethane aortic heart valves showed ex-
cellent in vitro and in vivo hemodynamics after 20 weeks.
They were able to show that surgically implanted, flexible,
polymeric heart valve prosthesis was superior to current bio-
prosthesis in animal testing. The same type of polyurethane
valves has been used in our valved stent study. The thickness
of the polyurethane membrane is 100 to 150 mm, and the
thickness of the bovine jugular vein is 230  50 mm.14
Furthermore, Hashimoto and colleagues15 used an um-
brella-shaped polyurethane valve, which was attached to
the tip of newly devised repositionable stent valve in the aor-
tic position. They analyzed 2 different groups, one with
polyurethane valves and the second with the stentless valve.
In their study aortographic analysis of the first group showed
good function, and the diastolic pressure indicated no signif-
icant change. The other group (without the valve) showed
massive aortic regurgitation followed by dysfunction of
the native valve. These experiments were done in pigs,
and they were killed 1 hour after implantation. The postmor-
tem examination showed small amounts of thrombus inside
the polyurethane umbrella in group 1.
In this study we have demonstrated an excellent outcome
of the polyurethane valves in the pulmonary position in
a sheep model after 4 weeks. The results of our study showed
that the polyurethane valve can be used as a new stented
heart valve in a period of 4 weeks.
CONCLUSION
Percutaneously implanted polyurethane valves were eval-
uated during a 1-month period in an ovine model. The sheep
hearts demonstrated good structural and functional outcome.752 The Journal of Thoracic and Cardiovascular SurgWe thank Christine Haß and Marion Kru¨ger for their excellent
technical assistance and Klaus Mu¨ck for preparing the application
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